FDA BE: Truncate AUC for long half-life drug [Regulatives / Guidelines]

posted by d_labes  – Berlin, Germany, 2015-11-16 17:51 (3873 d 06:20 ago) – Posting: # 15642
Views: 3,265

Dear John!

Forgotten your own question on the same subject :-D? And Helmut's answer? Here is it.

Ok it's from 2012. But AFAIK there is no new information on this subject meanwhile. Beside the fact that for highly variable drugs truncation shouldn't be used. See f.i. this thread.

Regards,

Detlew

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
133 visitors (0 registered, 133 guests [including 27 identified bots]).
Forum time: 01:11 CEST (Europe/Vienna)

Scientists often have a naïve faith that
if only they could discover enough facts about a problem,
these facts would somehow arrange themselves
in a compelling and true solution.    Theodosius Dobzhansky

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5